Hideaki Hirashima

Mr. Hideaki Hirashima

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
HHHideaki Hirashima
Hideaki Hirashima
TOTomohiro Ono
Tomohiro Ono
MNMitsuhiro Nakamura
Mitsuhiro Nakamura
YMYuki Miyabe
Yuki Miyabe
NMNobutaka Mukumoto
Nobutaka Mukumoto
TMTakashi Mizowaki
Takashi Mizowaki

20 June 2021 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
PDF file
HHHideaki Hirashima
Hideaki Hirashima
MNMitsuhiro Nakamura
Mitsuhiro Nakamura
NMNobutaka Mukumoto
Nobutaka Mukumoto
RARyo Ashida
Ryo Ashida
KFKota Fujii
Kota Fujii
TMTAKASHI MIZOWAKI
TAKASHI MIZOWAKI
Purpose: This study aimed to assess dosimetric indices of RapidPlan model‐based plans for different energies (6, 8, 10, and 15 MV; 6‐ and 10‐MV flattening filter‐free), multileaf collimator (MLC) types (Millennium 120, High Definition 120, dual‐layer MLC), and disease sites (head and neck, pancreatic, and rectal cancer) and compare these parameters with those of clinical plans.Methods: RapidPlan models in the Eclipse version 15.6 were used with the data of 28, 42, and 20 patients with head and neck, pancreatic, and rectal cancer, respectively. RapidPlan models of head and neck, pancreatic, and rectal cancer were created for TrueBeam STx (High Definition 120) with 6 MV, TrueBeam STx with 10‐MV flattening filter‐free, and Clinac iX (Millennium 120) with 15 MV, respectively. The models were used to create volumetric‐modulated arc therapy plans for a 10‐patient test dataset using all energy and MLC types at all disease sites. The Holm test was used to compare multiple dosimetric indices in different treatment machines and energy types.Results: The dosimetric indices for planning target volume and organs at risk in RapidPlan model‐based plans were comparable to those in the clinical plan. Furthermore, no dose difference was observed among the RapidPlan models. The variability among RapidPlan models was consistent regardless of the treatment machines, MLC types, and energy.Conclusions: Dosimetric indices of RapidPlan model‐based plans appear to be comparable to the ones based on clinical plans regardless of energies, MLC types, and disease sites. The results suggest that the RapidPlan model can generate treatment plans independent of the type of treatment machine.

25 July 2022 in Brachytherapy
Verified
Journal Article
Closed access
HTHidenobu Tachibana
Hidenobu Tachibana
YWYusuke Watanabe
Yusuke Watanabe
SKShogo Kurokawa
Shogo Kurokawa
TMTakuya Maeyama
Takuya Maeyama
THTomoyuki Hiroki
Tomoyuki Hiroki
TATetsuo Akimoto
Tetsuo Akimoto

14 February 2018 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
HHHideaki Hirashima
Hideaki Hirashima
MNMitsuhiro Nakamura
Mitsuhiro Nakamura
YMYuki Miyabe
Yuki Miyabe
MUMegumi Uto
Megumi Uto
KNKiyonao Nakamura
Kiyonao Nakamura
TMTAKASHI MIZOWAKI
TAKASHI MIZOWAKI
Volumetric-modulated Dynamic WaveArc therapy (VMDWAT) is a non-coplanar continuous volumetric modulated radiation therapy (VMAT) delivery technique. Here, we monitored mechanical errors and their impact on dose distributions in VMDWAT using logfiles throughout the course of treatment. Fifteen patients were enrolled (2 skull base tumor patients and 13 prostate cancer patients). VMDWAT plans were created for the enrolled patients. The prescribed dose for the skull base tumor was set as 54 Gy at 1.8 Gy per fraction, and that for the prostate cancer was set as 72 to 78 Gy at 2 Gy per fraction. We acquired logfiles to monitor mechanical errors and their impact on dose distribution in each fraction. The root mean square error (RMSE) in the multi-leaf collimator (MLC), gantry angle, O-ring angle and monitor unit (MU) were calculated using logfiles throughout the course of VMDWAT for each patient. The dosimetric impact of mechanical errors throughout the course of VMDWAT was verified using a logfile-based dose reconstruction method. Dosimetric errors between the reconstructed plans and the original plans were assessed. A total of 517 datasets, including 55 datasets for the 2 skull base tumor patients and 462 datasets for the 13 prostate cancer patients, were acquired. The RMSE values were less than 0.1 mm, 0.2°, 0.1°, and 0.4 MU for MLC position, gantry angle, O-ring angle, and MU, respectively. For the skull base tumors, the absolute mean dosimetric errors and two standard deviations throughout the course of treatment were less than 1.4% and 1.1%, respectively. For prostate cancer, these absolute values were less than 0.3% and 0.5%, respectively. The largest dosimetric error of 2.5% was observed in a skull base tumor patient. The resultant dosimetric error in the accumulated daily delivered dose distribution, in the patient with the largest error, was up to 1.6% for all dose-volumetric parameters relative to the planned dose distribution. MLC position, gantry rotation, O-ring rotation and MU were highly accurate and stable throughout the course of treatment. The daily dosimetric errors due to mechanical errors were small. VMDWAT provided high delivery accuracy and stability throughout the course of treatment. UMIN000023870 . Registered: 1 October 2016.

7 January 2021 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
MNMitsuhiro Nakamura
Mitsuhiro Nakamura
MNMegumi Nakao
Megumi Nakao
NMNobutaka Mukumoto
Nobutaka Mukumoto
RARyo Ashida
Ryo Ashida
HHHideaki Hirashima
Hideaki Hirashima
TMTAKASHI MIZOWAKI
TAKASHI MIZOWAKI
Purpose . To introduce the concept of statistical shape model (SSM)-based planning organ-at-risk volume (sPRV) for pancreatic cancer patients. Methods . A total of 120 pancreatic cancer patients were enrolled in this study. After correcting inter-patient variations in the centroid position of the planning target volume (PTV), four different SSMs were constructed by registering a deformable template model to an individual model for the stomach and duodenum. The sPRV, which focused on the following different components of the inter-patient variations, was then created: Scenario A: shape, rotational angle, volume, and centroid position; Scenario B: shape, rotational angle, and volume; Scenario C: shape and rotational angle; and Scenario D: shape. The conventional PRV (cPRV) was created by adding an isotropic margin R (3–15 mm) to the mean shape model. The corresponding sPRV was created from the SSM until the volume difference between the cPRV and sPRV was less than 1%. Thereafter, we computed the overlapping volume between the PTV and cPRV (OL c ) or sPRV (OL s ) in each patient. OL s being larger than OL c implies that the local shape variations in the corresponding OAR close to the PTV were large. Therefore, OL s /OL c was calculated in each patient for each R- value, and the median value of OL s /OL c was regarded as a surrogate for plan quality for each R- value. Results . For R = 3 and 5 mm, OL s /OL c exceeded 1 for the stomach and duodenum in all scenarios, with a maximum OL s /OL c of 1.21. This indicates that smaller isotropic margins did not sufficiently account for the local shape changes close to the PTV. Conclusions . Our results indicated that, in contrast to conventional PRV, SSM-based PRVs, which account for local shape changes, would result in better dose sparing for the stomach and duodenum in pancreatic cancer patients.

6 April 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
SHShinya Hiraoka
Shinya Hiraoka
HHHideaki Hirashima
Hideaki Hirashima
MNMitsuhiro Nakamura
Mitsuhiro Nakamura
FTFumiya Tanaka
Fumiya Tanaka
HAHiroki Adachi
Hiroki Adachi
TMTAKASHI MIZOWAKI
TAKASHI MIZOWAKI
OXRAY is a new O-ring-shaped radiotherapy system delivering biaxially rotational dynamic-radiation therapy (BROAD-RT), a technique that enables non-coplanar volumetric-modulated arc therapy (VMAT) for large target volumes without requiring couch movement. The purpose of this study was to evaluate the benefits of BROAD-RT and to perform an integration test to confirm the plan deliverability and its accuracy from the treatment planning system to OXRAY for patients with nasopharyngeal carcinoma. We compared treatment plans for BROAD-RT and coplanar VMAT (COVMAT) created in RayStation for 15 patients with nasopharyngeal cancer using the Wilcoxon signed-rank test. P values less than 0.05 were considered statistically significant. Additionally, we confirmed the plan delivery accuracy of BROAD-RT from the treatment planning system to OXRAY; gamma passing rates (GPRs) and delivery time were evaluated. The criteria for pass and fail were ≥95 % at γ3%2 mm. BROAD-RT significantly improved the homogeneity and conformity index of planning target volume and reduced dose volume indices compared with COVMAT in D0.03 cc for the brainstem, D0.03 cc for the left optic nerve, D0.03 cc for the brachial plexus, Dmean for each submandibular gland, Dmean for the oral cavity, and Dmean for each parotid gland. All plans for BROAD-RT passed the integration test; the mean GPR (3 %/2 mm) was above 95 % and the median delivery time was 209 s. BROAD-RT delivered by OXRAY passed the integration test, and it demonstrated the potential benefit of improving the dose distribution compared with COVMAT for patients with nasopharyngeal carcinoma.